A Clinical Study on Arsenic Trioxide Combined with Cisplatin in the Treatment of Malignant Pleural Effusion_West China Medical Journal

Authors：

Department of Oncology, Chengdu Fifth People’s Hospital, Chengdu, Sichuan 611130, P. R. China;

Corresponding?author：

Keywords：

三氧化二砷; 順鉑; 胸腔內灌注; 惡性胸腔積液

DOI：

10.7507/1002-0179.20130221

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　觀察三氧化二砷聯合順鉑腔內注射治療惡性胸腔積液的療效和毒副反應。方法　2011年9月－2012年9月，將惡性胸腔積液患者60例，隨機分為治療組和對照組，每組各30例。在胸腔積液充分引流后，治療組胸腔內注射三氧化二砷20 mg聯合順鉑60 mg；對照組只給予胸腔灌注順鉑60 mg，胸腔灌注化學療法藥物兩組均1次/周，共3次。觀察療效及不良反應。結果　治療組和對照組的有效率分別為93.3%和56.7%（P＜0.05）。治療組和對照組的一般狀況改善率分別為70.0%和40.0%（P＜0.05）。兩組的不良反應相近。結論　三氧化二砷聯合順鉑腔內注射治療惡性胸腔積液具有協同增效作用，不良反應小。

Citation： YANG XueMei,CHEN YuanHang,ZENG Shouqun,DAI Gangyi,ZENG Guilin,MENG Yousheng.. A Clinical Study on Arsenic Trioxide Combined with Cisplatin in the Treatment of Malignant Pleural Effusion. West China Medical Journal, 2013, 28(5): 707-709. doi: 10.7507/1002-0179.20130221 Copy

1.	Muduly D, Deo S, Subi Ts, et al. An update in the management of malignant pleural effusion[J]. Indian J Palliat Care, 2011, 17(2): 98-103.
2.	孫燕, 石遠凱. 臨床腫瘤內科手冊[M]. 5版. 北京：人民衛生出版社, 2007: 147-149.
3.	殷蔚伯, 余子豪, 徐國鎮, 等. 腫瘤放射治療學[M]. 4版. 北京:中國協和醫科大學出版社: 2007: 1349.
4.	Steger V, Mika U, Toomes H, et al. Who gain most? A 10-year experience with 611 thoracoscopic talc pleurodeses[J]. J Ann Thorac Surg, 2007, 83(6): 1940-1945.
5.	Aelony Y. Dry talc pleurodesis via chest tube[J]. Chest, 2003, 123(1): 308.
6.	Neragi Miandoab S. Malignant pleural effusion current and evolving approaches for its diagnosis and management[J]. Lung Cancer, 2006, 54(1): 1-9.
7.	Cerimagic Z, Guska S, Pilav I, et al. The using doxycycline in procedure chemical pleurodesis of malignancy pleural effusion[J]. Med Arh, 2006, 60(6): 360-363.
8.	林新義, 劉海燕, 張丹, 等. 三氧化二砷治療惡性胸腔積液15例[J]. 丹東醫藥, 2007, 1: 18.
9.	Nemeti B, Gregus Z. Reduction of arsenate to arsenite in hepatic cytosol[J]. Toxicol Sci, 2002, 70: 4-12.
10.	黃小軍. 三氧化二砷誘導細胞凋亡的調節. 中國血液病雜志, 1999, 19(5): 52.
11.	Saurai T, Ochiai M, Kojima C, et al. Role of glutathione in dimethy-larsinic acid-induced apoptosis[J]. Toxicol Appl Pharmacol, 2004, 198: 354-365.
12.	張鵬, 王樹葉, 胡龍虎, 等. 三氧化二砷注射液治療72例急性早幼粒細胞白血病[J]. 中華血液學雜志, 1996, 17(2): 58-61.
13.	Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide(As2O3)in the treatment of acute promyelocytic leukemia(APL):Ⅱ. Clinical efficacy and pharmacokinetics in relapsed patients[J]. Blood, 1997, 89(9): 3354-3360.
14.	Han B, Zhou G, Zhang Q, et al. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp[J]. J Exp Ther Oncol, 2004, 4(4): 335-342.
15.	Matsui W, Smith BD, Vala M, et al. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukemia[J]. Br J Haematol, 2005, 128(6): 853-862.
16.	Karasulu HY, Karabulut B, Kantarci G, et al. Preparation of arsenic trioxide loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line[J]. Drug Deliv, 2004, 11(6): 345-350.
17.	Kang SH, Song JH, Kang HK, et al. arsenic trioxide-induced apoptosis is in dependent of stress-responsive signaling pathway but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cell[J]. Exp Mol Med, 2003, 35(2): 83-90.
18.	顧琴龍, 沈佰華, 李寧麗, 等.氧化砷誘導胃癌細胞株凋亡的初步研究[J]. 中華消化雜志, 1998, 18(2): 69-71.
19.	劉靜冰, 秦叔逵, 錢鈞, 等.三氧化二砷注射液治療晚期胰腺癌的臨床研究[J].臨床腫瘤學雜志, 2005, 10(2): 117-119.
20.	劉連新, 朱安龍, 陳煒, 等. 三氧化二砷對原發性肝癌的作用及其機理研究[J].中華外科雜志, 2005, 43(1): 33-36.
21.	張莉, 王玲, 宋維華, 等.三氧化二砷通過升高細胞內鈣離子濃度介導肺癌細胞凋亡[J]. 中華藥理學通報, 2004, 20(8): 867-870.
22.	魏虎來, 姚小健, 李宇寧, 等. 三氧化二砷抑制K562/ADM細胞P-糖蛋白表達并提高化療藥物的敏感性[J]. 中華血液學雜志, 2003, 24(1): 28-31.
23.	王秀麗, 孔力, 趙瑾瑤, 等. 三氧化二砷逆轉人乳腺癌MCF-7/ADM細胞耐藥的機制研究[J]. 中華腫瘤雜志, 2002, 24(4): 339-343.
24.	趙園園, 金鋒, 梁軍, 等. 三氧化二砷對人胃癌耐藥細胞系SGC7901/ADM耐藥逆轉及凋亡誘導作用的探討[J]. 中國腫瘤臨床, 2005, 32(11): 611-613.
25.	Li H, Zhu X, Zhang Y, et al. Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction[J]. J Exp Clin Cancer Res, 2009, 28: 110.
26.	韓冰, 石玉枝, 雷建民. 三氧化二砷對肺腺癌細胞凋亡及肺耐藥蛋白基因多藥耐藥蛋白基因表達的影響[J]. 中國實用內科雜志, 2005, 25(3): 243-244.

1. 　Muduly D, Deo S, Subi Ts, et al. An update in the management of malignant pleural effusion[J]. Indian J Palliat Care, 2011, 17(2): 98-103.
2. 　孫燕, 石遠凱. 臨床腫瘤內科手冊[M]. 5版. 北京：人民衛生出版社, 2007: 147-149.
3. 　殷蔚伯, 余子豪, 徐國鎮, 等. 腫瘤放射治療學[M]. 4版. 北京:中國協和醫科大學出版社: 2007: 1349.
4. 　Steger V, Mika U, Toomes H, et al. Who gain most? A 10-year experience with 611 thoracoscopic talc pleurodeses[J]. J Ann Thorac Surg, 2007, 83(6): 1940-1945.
5. 　Aelony Y. Dry talc pleurodesis via chest tube[J]. Chest, 2003, 123(1): 308.
6. 　Neragi Miandoab S. Malignant pleural effusion current and evolving approaches for its diagnosis and management[J]. Lung Cancer, 2006, 54(1): 1-9.
7. 　Cerimagic Z, Guska S, Pilav I, et al. The using doxycycline in procedure chemical pleurodesis of malignancy pleural effusion[J]. Med Arh, 2006, 60(6): 360-363.
8. 　林新義, 劉海燕, 張丹, 等. 三氧化二砷治療惡性胸腔積液15例[J]. 丹東醫藥, 2007, 1: 18.
9. 　Nemeti B, Gregus Z. Reduction of arsenate to arsenite in hepatic cytosol[J]. Toxicol Sci, 2002, 70: 4-12.
10. 　黃小軍. 三氧化二砷誘導細胞凋亡的調節. 中國血液病雜志, 1999, 19(5): 52.
11. 　Saurai T, Ochiai M, Kojima C, et al. Role of glutathione in dimethy-larsinic acid-induced apoptosis[J]. Toxicol Appl Pharmacol, 2004, 198: 354-365.
12. 　張鵬, 王樹葉, 胡龍虎, 等. 三氧化二砷注射液治療72例急性早幼粒細胞白血病[J]. 中華血液學雜志, 1996, 17(2): 58-61.
13. 　Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide(As2O3)in the treatment of acute promyelocytic leukemia(APL):Ⅱ. Clinical efficacy and pharmacokinetics in relapsed patients[J]. Blood, 1997, 89(9): 3354-3360.
14. 　Han B, Zhou G, Zhang Q, et al. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp[J]. J Exp Ther Oncol, 2004, 4(4): 335-342.
15. 　Matsui W, Smith BD, Vala M, et al. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukemia[J]. Br J Haematol, 2005, 128(6): 853-862.
16. 　Karasulu HY, Karabulut B, Kantarci G, et al. Preparation of arsenic trioxide loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line[J]. Drug Deliv, 2004, 11(6): 345-350.
17. 　Kang SH, Song JH, Kang HK, et al. arsenic trioxide-induced apoptosis is in dependent of stress-responsive signaling pathway but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cell[J]. Exp Mol Med, 2003, 35(2): 83-90.
18. 　顧琴龍, 沈佰華, 李寧麗, 等.氧化砷誘導胃癌細胞株凋亡的初步研究[J]. 中華消化雜志, 1998, 18(2): 69-71.
19. 　劉靜冰, 秦叔逵, 錢鈞, 等.三氧化二砷注射液治療晚期胰腺癌的臨床研究[J].臨床腫瘤學雜志, 2005, 10(2): 117-119.
20. 　劉連新, 朱安龍, 陳煒, 等. 三氧化二砷對原發性肝癌的作用及其機理研究[J].中華外科雜志, 2005, 43(1): 33-36.
21. 　張莉, 王玲, 宋維華, 等.三氧化二砷通過升高細胞內鈣離子濃度介導肺癌細胞凋亡[J]. 中華藥理學通報, 2004, 20(8): 867-870.
22. 　魏虎來, 姚小健, 李宇寧, 等. 三氧化二砷抑制K562/ADM細胞P-糖蛋白表達并提高化療藥物的敏感性[J]. 中華血液學雜志, 2003, 24(1): 28-31.
23. 　王秀麗, 孔力, 趙瑾瑤, 等. 三氧化二砷逆轉人乳腺癌MCF-7/ADM細胞耐藥的機制研究[J]. 中華腫瘤雜志, 2002, 24(4): 339-343.
24. 　趙園園, 金鋒, 梁軍, 等. 三氧化二砷對人胃癌耐藥細胞系SGC7901/ADM耐藥逆轉及凋亡誘導作用的探討[J]. 中國腫瘤臨床, 2005, 32(11): 611-613.
25. 　Li H, Zhu X, Zhang Y, et al. Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction[J]. J Exp Clin Cancer Res, 2009, 28: 110.
26. 　韓冰, 石玉枝, 雷建民. 三氧化二砷對肺腺癌細胞凋亡及肺耐藥蛋白基因多藥耐藥蛋白基因表達的影響[J]. 中國實用內科雜志, 2005, 25(3): 243-244.

Previous Article
Application of Dual-source Low-dose Computed Tomography in Common Chest Inspection
Next Article
Clinicopathological Analysis of Primary Signet Ring Cell Adenocarcinoma of the Lung

West China Medical Journal

A Clinical Study on Arsenic Trioxide Combined with Cisplatin in the Treatment of Malignant Pleural Effusion

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content